Patient blood management in India - Review of current practices and feasibility of applying appropriate standard of care guidelines. A position paper by an interdisciplinary expert group

Ajay Gandhi, Klaus Görlinger1, Sukesh C. Nair2, Poonam M. Kapoor3, Anjan Trikha4, Yatin Mehta5, Anil Handoo6, Anil Karlekar7, Jyoti Kotwal8, Joseph John9, Shashikant Apte10, Vijay Vohra11, Gajendra Gupta12, Aseem K. Tiwari13, Anjali Rani14, Sweta A. Singh15

Head – Clinical Affairs, Instrumentation Laboratory India Pvt Ltd, 1Department of Anaesthesiology, Pain Medicine and Critical Care, In Charge Trauma Intensive Care Unit and Trauma Anaesthesia, JPN Apex Trauma Centre, 2Department of Cardiac Anaesthesia, All India Institute of Medical Sciences, 3Department of Laboratory Medicine, BLK Superspeciality Hospital, 4Department of Cardiac Anaesthesia, Fortis Escorts Heart Institute, New Delhi, 5Department of Haematology, Sir Gangaram Hospital, 6Department of Liver Transplant Anaesthesia, Max Super speciality Hospital, New Delhi, 7Department of Transfusion Medicine and Immunohematology, Christian Medical College, Vellore, Tamil Nadu, Departments of 8Cardiac Anaesthesia, 9Liver Transplant Anaesthesia and 10Transfusion Medicine, Medanta the Medicity, Gurugram, Haryana, 11Department of Haematology and Bone Marrow Transplant, Christian Medical College, Ludhiana, Punjab, 12Department of Clinical Haematology, Sahyadri Hospital, Pune, Maharashtra, 13Medical Director and Head, Laboratory and Blood Bank, Santokhda Durlabhji Hospital, Jaipur, Rajasthan, 14Department of Obstetrics and Gynaecology, Banaras Hindu University, Varanasi, Uttar Pradesh, India, 15Medical Director, TEM Innovations/PBM Instrumentation Laboratory, Munich, Germany

Abstract

In a developing country like India, with limited resources and access to healthcare facilities, dealing with massive hemorrhage is a major challenge. This challenge gets compounded by pre-existing anemia, hemostatic disorders, and logistic issues of timely transfer of such patients from peripheral hospitals to centers with adequate resources and management expertise. Despite the awareness amongst healthcare providers regarding management modalities of bleeding patients, no uniform Patient Blood Management (PBM) or perioperative bleeding management protocols have been implemented in India, yet. In light of this, an interdisciplinary expert group came together, comprising of experts working in transfusion medicine, hematology, obstetrics, anesthesiology and intensive care, to review current practices in management of bleeding in Indian healthcare institutions and evaluating the feasibility of implementing uniform PBM guidelines. The specific intent was to perform a gap analysis between the ideal and the current status in terms of practices and resources. The expert group identified interdisciplinary education in PBM and bleeding management, bleeding history, viscoelastic and platelet function testing, and the implementation of validated, setting-specific bleeding management protocols (algorithms) as important tools in PBM and perioperative bleeding management. Here, trauma, major surgery, postpartum hemorrhage, cardiac and liver surgery are the most common clinical settings associated with massive blood loss. Accordingly, PBM should be implemented as a multidisciplinary and practically applicable concept in India in a timely manner in order to optimize the use the precious resource blood and to increase patients’ safety.

Keywords: Bleeding, blood transfusion, coagulopathy, hemorrhage, hemostasis testing, patient blood management, patient safety, point-of-care testing, thromboelastometry

Address for correspondence: Dr Ajay Gandhi,
Clinical Affairs, Instrumentation Laboratory India Private Limited.
1471-76, Agrawal Millennium Tower II, Plot Number E-4, Netaji Subhash Place, Pitampura, New Delhi, India.
E-mail: agandhi@werfen.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Gandhi A, Görlinger K, Nair SC, Kapoor PM, Trikha A, Mehta Y, et al. Patient blood management in India - Review of current practices and feasibility of applying appropriate standard of care guidelines. A position paper by an interdisciplinary expert group. J Anaesthesiol Clin Pharmacol 2021;37:3-13.
Submitted: 06-Jul-2020 Revised: 09-Sep-2020 Accepted: 04-Oct-2020 Published: 10-Apr-2021

Access this article online

Quick Response Code:

Website: www.joacp.org
DOI: 10.4103/joyacp.JOACP_410_20
Introduction

The prognosis of excessive bleeding patients, particularly during the perioperative or periprocedural period, is dependent on the clinical situation, patient’s hemostatic ability and the clinician’s experience with bleeding management. The utility of the pre-operative evaluation, the clinical and diagnostic assessment during bleeding, and the accessibility to and availability of procedures, pharmacologic agents or blood components to arrest bleeding, are the most crucial aspects of management of abnormal bleeding.

Clinical history of bleeding diathesis and family history of same is the first step that can predict abnormal bleeding. Most centers rely on standard laboratory tests to predict bleeding during surgical interventions despite their proven limited utility in elective and acute settings. The medical/health education curriculum is structured on stratified disciplines, and there is a conspicuous absence of a multidisciplinary approach model; The basic medical education still needs to define and incorporate the principles and protocols of patient blood management. While there is a non-uniform adoption of blood component therapy, the use of point-of-care viscoelastic testing in diagnosing as well as guiding the management of such cases, also, is limited to, mostly, private healthcare facilities based in large cities.

This interdisciplinary expert group evaluated all challenges and current practices and attempted to address them in a structured manner based on a detailed questionnaire designed and developed by the group itself. This expert group aims to provide consensus statements towards identifying steps which can uniformly predict abnormal and excessive bleeding and, at the same time, minimizing perioperative blood loss by rational use of blood products and hemostatic agents as an essential part of a Patient Blood Management program. In this first step of the exercise, a consensus was developed, the focus of which is on assessing the competence of patient’s hemostasis as well as the availability of resources at various levels of healthcare facilities in India. Some broad consensus statements on managing an unexpected case of abnormal bleeding in select clinical settings have also been made. The consensus from this expert group is expected to pave the way for concerned medical disciplines and associations towards developing specific algorithms for the management of perioperative bleeding in various clinical settings, particularly customized for India, as an essential part of a Patient Blood Management and patient safety programs in India.

Methods

Establishment of an interdisciplinary expert group

The unmet needs and poorly understood protocols of managing perioperative bleeding led to a group of experts, belonging to different disciplines from across the country, working in government and private healthcare institutions, to come together and discuss, evaluate and strategize the modus operandi to deal with such clinical situations. This expert group first met on November 21st, 2018 in New Delhi, India, with the agenda based on common clinical situations encountered, challenges faced, and resources required to manage them.

Development of the questionnaire

Following the meeting, and a series of communications around the summary of the discussions held, a questionnaire was developed as a systematic approach to cover a broad spectrum of clinical, scientific, technical, and referential aspects. The expert group thoroughly validated the questionnaire. The questionnaire was sent to all the experts and all of them responded with their inputs within the given timeline.

Consensus statements and manuscript development

Basis inputs to the questionnaire received, a subcommittee started summing up the responses. Following a series of communications, several virtual and one physical meeting, the opinions, suggestions, and recommendations were summarized in the final manuscript. Some of the terminology used is as follows:

- **Expert group “agrees/suggests”** —when more than 50% of members agreed to a statement.
- **Expert group “recommends”** —when more than 75% of members agreed to a consensus statement.
- **No consensus** —when less than 50% of members agreed.
- **Negative recommendation** —when the expert group recommended against a practice.

Evidence and references

This is a consensus statement based on the experience and expertise of the members of the interdisciplinary expert group. The expert group members have quoted appropriate references from literature to support their opinions and statements.
Results, Consensus and Discussions

Abnormal bleeding

Abnormal bleeding is defined as any perioperative or peri-procedural bleeding exceeding the usual (expected) average for a given surgery or procedure based, either on surgeon’s subjective opinion or, as in some cases, pre-defined established criteria. Such a bleeding may require (massive) transfusions adversely affecting hospital course and patient outcomes. The common conditions associated with perioperative abnormal bleeding are listed in Table 1.

Bleeding history assessment

Bleeding and medication history is an essential tool to evaluate the risk of abnormal bleeding before a surgical procedure or intervention. Ideally, any laboratory screening should only be done if bleeding history is indicative. However, minor bleeding disorders could be missed even with an elaborate history. Globally, the International Society of Thrombosis and Haemostasis (ISTH) Bleeding Assessment Tool (BAT) score is the most commonly used tool.

Adequacy and reliability of the bleeding history

Bleeding history (or medical history, per se) is limited by inadequacy in standardization and evaluation as well as, to some extent, non-reliability of the patient; the expert group agrees that there is a need to understand the utility of ISTH-BAT score from that perspective. The expert group suggests assessing the confidence intervals for ISTH-BAT score. The expert group recommends designing a bleeding score that could aid in quick bedside evaluation of hemostatic challenges like platelet disorders and clotting factor deficiency, leaving aside the ones that evaluate connective tissue factors. The expert group recommends that there should not be an attempt to supplement the history by standard laboratory tests. The expert group consensus on medical history for assessing patient’s bleeding risk are presented in Table 2.

Laboratory screening tests for perioperative abnormal bleeding

The aim of preoperative screening is to predict the risk of bleeding before surgery or invasive interventions. Traditionally, the usual pre-operative screen includes bleeding time (BT), platelet count (PLC) or complete blood count (CBC), prothrombin time (PT) and activated partial thromboplastin time (APTT). However, the positive predictive value of these tests is limited. Only a few follow up the abnormal screen test with mixing studies for further evaluation although these studies could miss minor factor deficiencies. Some centers go for platelet function testing since BT is not very reliable or reproducible. The expert group recommends against the use of BT as a pre-operative test. Notably, the most common causes of bleeding, platelet function defects and Von Willebrand disease (vWD) are not depicted by these standard lab tests. Also, a common reason for a prolonged APTT in children with infection, e.g., tonsillitis, is positive transient lupus anticoagulant. There is growing consensus and the expert group agrees that a collaborative and cost-effective strategic approach is required to identify patients with high

Table 1: Conditions associated with abnormal bleeding

| Bleeding disorder (potential bleeder)                |
|---------------------------------------------------|
| Hereditary                                        |
| Acquired                                          |
| Iatrogenic                                        |
| Comorbid conditions                               |
| Ante/Postpartum hemorrhage                        |
| Chronic Liver disease                             |
| Chronic Renal disease                             |
| Procedure/external injury related                 |
| Surgery - Liver transplant/Cardiac (including redo) surgery |
| Trauma                                            |
| Snake bite                                        |
| Complex mechanism                                 |
| DIC                                               |
| Dilutional coagulopathy                           |
| Patient’s clinical condition                      |
| Thrombocytopenia                                  |
| Hypothermia                                       |
| Acidosis                                          |
| Low Haematocrit/Haemoglobin                       |
| Hypocalcaemia                                     |
| Drugs (anti-platelet drugs, anticoagulants)       |
| Evolutionary                                      |
| Inappropriate blood component transfusion         |
| Inadequate blood component transfusion            |
| Massive trauma                                    |

Table 2: Expert group recommendation for assessment of patient’s bleeding risk

| History of bleeding:                      |
|------------------------------------------|
| Bleeding during infancy (e.g., umbilical stump bleeding) and childhood (e.g., bleeding with loss of deciduous teeth);  |
| Bleeding during adolescence and adulthood (menstruation and pregnancy);  |
| Any bleeds severe enough to require surgical intervention, nasal packing or cautery, a visit to the emergency department, or transfusion.  |
| Any history of unusual bleeding or spontaneous bleeding into mucosa or muscles even with minimal cuts/bruises/brushing.  |
| Dark stools/blood in sputum/hematemesis   |
| History of iron deficiency or iron-responsive anemia |
| Family history relevant to risk of bleeding disorder |
| Past/currently used drugs & medication    |
| Low dose aspirin                          |
| Antiplatelet drugs                         |
| Anticoagulants                            |
| Consanguinity in family                   |
bleeding risk in the form of an adequate and appropriate medical and bleeding history along with laboratory tests, where needed.

**Predicting the likelihood of bleeding or identifying “abnormal” bleeding**

Not all bleeding tendencies will be evident on history, nor will laboratory tests pick up all cases of abnormal bleeding. The expert group recommends a structured and collaborative approach as given in Table 3. As depicted in Table 3, none of the tests, by itself, is sensitive or specific to predict the risk of bleeding or identify the abnormal one during an episode. Most often, abnormal bleeding is based on a combination of haemostasis issues. Furthermore, not all the tests are available at all levels of health care, particularly in primary health care facilities in developing countries. Often, the “ideal best” test is supplemented by the “available best” test. The expert group agrees that there is a need to fill the gap between the “ideal best” and the “available best”. There was no consensus formed in the expert group on whether the “ideal best” is a true or a surrogate replacement of the “available best”. The expert group recommends that whenever and wherever possible, the appropriate tests should be done at the baseline. They may be repeated as per other validated protocols or depending on the patient’s clinical condition.

**Stratifying resources based on health-care facilities**

The expert group suggests the minimum infrastructure which must be available at a health care center to manage cases with or at high risk of perioperative abnormal bleeding. Health care facilities in most developing countries are primarily of three categories. Primary health-care facility means either a government primary healthcare center or a nursing home or a very small hospital with limited health care services. Secondary health-care facility means a government community health center (CHC) or a small hospital in a non-metro city. Tertiary health-care facility means a medical university hospital or a large private hospital or an apex governmental institute or national reference hospital. The expert group recommended resources for dealing with cases of abnormal bleeding are given in Table 4.

Blood components and other products available (Not in order of preference or prevalence) in India are:

- A. Packed red blood cells (PRC)
- B. Fresh frozen plasma (FFP)
- C. Platelet concentrate (Random Donor/Single Donor)
- D. Cryoprecipitate
- E. Fibrinogen concentrate
- F. Recombinant factor VIIa
- G. Tranexamic acid (TXA)/Epsilon Aminocaproic Acid (EACA)
- H. Prothrombin complex concentrate (PCC)
- I. Antidotes - Protamine, PCC, Idarucizumab
- J. Desmopressin.

**Medical/Health education curriculum**

The medical/health education system of India is very elaborate and is updated continuously. However, the expert group agrees that there is a scope of improvement. The expert group suggests revising the medical or health education curriculum to a more organized, multi-disciplinary and resourceful in dealing with perioperative abnormal bleeding. A transition from traditional laboratory methods towards viscoelastic testing in managing bleeding patients, wherever feasible, could shift clinical practice from fixed-ratio-driven massive transfusion protocols (MTPs) to goal-directed therapy and patient blood management. Many of the patient blood management concepts and protocols adopted globally are relevant and available in countries like India; however, many hospitals may need educational and logistic support in implementation.

**Clinical conditions with high bleeding risk**

Many clinical conditions are associated with a higher bleeding risk, example—von Willebrand Disease, hemophilia, liver/kidney diseases, specific medications—aspirin, antiplatelet drugs, NSAIDs, oral anticoagulants (vitamin K antagonists and direct oral anticoagulants (DOACs)). Furthermore, certain procedures are associated with excessive bleeding such as major orthopedic surgery (e.g., total hip/knee arthroplasty), major abdominal surgery (e.g., liver resection and transplantation, tumor resection, pancreatic surgery), cardiovascular-thoracic surgery, etc., Such procedures, along with pre-existing hemostatic disorder or those acquired during the procedure, may cause massive bleeding. In such cases, the effectiveness of bleeding risk assessment tools decreases. The expert group recommends that, in all such cases, adequate and appropriate diagnostic screening tests must be performed. Here, standard laboratory tests (SLTs) or, preferably, viscoelastic testing (VET) are more appropriate. VET provides a comprehensive picture with shorter turn-around time. Patients with or at risk of abnormal bleeding must be referred to an appropriate health care facility to ensure optimal management and allow for improved patient outcomes.[25-30]

**Massive transfusion protocols and the need for “shock packs”**

Various definitions of massive blood transfusion (MBT) have been published in the medical literature.[31-38] The principles of management of any acute/massive blood loss involve the management of intravascular blood volume and loss of blood components and management strategies specific to the
### Table 3: Tests recommended for predicting bleeding or identifying abnormal bleeding (NOT in order of preference)

| Abnormal bleeding condition | Utility of clinical history | Recommended test | Best lab based test | Best POC test |
|-----------------------------|-----------------------------|------------------|--------------------|---------------|
| Hereditary bleeding disorders |                            |                  |                    |               |
| Hemophilia                  | Effective                    | Single factor assays | APTT and Mixing    | INTEM; Kaolin-TEG |
| VWD                         | Effective                    | VWF: RCo/VWF: Ag  | PFA-100/200/Multiplate | Multiplate |
| Platelet dysfunction        | Effective                    | Aggregometry/Flow cytometer | Light transmission aggregometry | Multiplate/ROTEM platelet/Verify now/TEG platelet mapping |
| Acquired bleeding disorders |                            |                  |                    |               |
| Factor deficiency (Fibrinogen, II, VII, VIII, X, XIII) | Not always | Factor assay and inhibitor assays | PT/APTT and Mixing | EXTEM, INTEM and FIBTEM; Kaolin-TEG, TEG-FF |
| Thrombocytopenia            | No                           | Platelet count with histogram | Platelet count | EXTEM and FIBTEM; Kaolin-TEG and TEG-FF |
| Iatrogenic Bleeding         | No                           | Hb and platelet count | Hb and platelet count | EXTEM, INTEM, FIBTEM and ROTEM platelet to exclude other reasons for bleeding |
| Liver condition             |                              |                  |                    |               |
| Cirrhosis                   | Unlikely                     | Factor assays (Fib and FV) D-Dimer | PT/APTT and Mixing | EXTEM and FIBTEM |
| Liver Transplant            | No                           | Factor assays (Fib and FV) D-Dimer | PT/APTT and Mixing | EXTEM, FIBTEM, INTEM and HEPTEM |
| Renal disease               | No                           | HCT and PFA      | PT/APTT and Mixing | EXTEM and FIBTEM |
| Peri- or post-partum        | No                           | Fibrinogen       | Fibrinogen        | EXTEM and FIBTEM; rapid-TEG and TEG-FF |
| Cardiac procedures          |                              |                  |                    |               |
| Aortic dissection           | No                           | EXTEM, FIBTEM, INTEM, HEPTEM; Kaolin-TEG, Heparinase-TEG, Rapid-TEG, TEG-FF/Multiplate/ROTEM platelet/Verify now/TEG platelet mapping; ACT | Fibrinogen/Platelet count/PT/APTT and Mixing | EXTEM, FIBTEM, INTEM and HEPTEM; Kaolin-TEG, Heparinase-TEG, raid-TEG and TEG-FF/Multiplate/ROTEM platelet/Verify now/TEG platelet mapping; ACT/blood gas analysis |
| CABG                        | No                           | EXTEM, FIBTEM, INTEM, HEPTEM; Kaolin-TEG, Heparinase-TEG, Rapid-TEG, TEG-FF/Multiplate/ROTEM platelet/Verify now/TEG platelet mapping; ACT | Fibrinogen/Platelet count/PT/APTT and Mixing | EXTEM, FIBTEM, INTEM and HEPTEM; Kaolin-TEG, Heparinase-TEG, raid-TEG and TEG-FF/Multiplate/ROTEM platelet/Verify now/TEG platelet mapping; ACT/blood gas analysis |
| ECMO                        | No                           | EXTEM, FIBTEM, INTEM, HEPTEM; Kaolin-TEG, Heparinase-TEG, Rapid-TEG, TEG-FF/Multiplate/ROTEM platelet/Verify now/TEG platelet mapping; ACT | Fibrinogen/Platelet count/PT/APTT and Mixing | EXTEM, FIBTEM, INTEM and HEPTEM; Kaolin-TEG, Heparinase-TEG, raid-TEG and TEG-FF/Multiplate/ROTEM platelet/Verify now/TEG platelet mapping; ACT/blood gas analysis |
| Heparin effect              | No                           | Anti-Xa          | Anti-Xa/ACT        | INTEM/HEPTEM CT-ratio/ Kaolin-TEG; Heparinase-TEG/ACT |
| Protamine overdose          | No                           | INTEM/HEPTEM CT-ratio | NA                  | INTEM/HEPTEM CT-ratio |
| Trauma                      | No                           | EXTEM and FIBTEM; Rapid-TEG and TEG-FF | Fibrinogen/Platelet count/PT/APTT and Mixing | EXTEM and FIBTEM; Rapid-TEG and TEG-FF/blood gas analysis |
| DIC                         | No                           | Fibrinogen, platelet count, D-dimer | PT/APTT and Mixing | EXTEM, FIBTEM and NA-HEPTEM; Multiplate/ROTEM platelet |
| Dilutional coagulopathy     | No                           | Fibrinogen and Platelet count | Fibrinogen/PT/APTT and Mixing | EXTEM and FIBTEM; Rapid-TEG and TEG-FF |
| Hypothermia                 | No                           | Test devices that adjust temperatures | VET adjusted to patient temperature | VET adjusted to patient temperature |

Contd...
Table 3: Contd...

| Abnormal bleeding condition | Utility of clinical history | Recommended test | Best lab based test | Best POC test |
|-----------------------------|-----------------------------|------------------|--------------------|--------------|
| Acidosis                    | Yes                         | Blood gas analysis | Blood gas analysis VET adjusted to patient temperature | Blood gas analysis |
| Low Hb/Hct                  | No                          | Hemoglobin       | Hemoglobin         | POC Hb devices/Blood gas analysis |

Table 4: Recommended resources for management of abnormal bleeding (NOT in order of preference)

| Resources/Tool                  | Primary HCF                                                                 | Secondary HCF                                                                 | Tertiary HCF                                                                 |
|---------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Protocol/Procedure*             | Yes                                                                          | Yes                                                                          | Yes                                                                          |
| Blood bank and component†       | Storage                                                                      | Storage with freezers/Blood bank with components                             | Blood bank with cryoprecipitate and platelet concentrate and fibrinogen concentrate |
| Pharmacological agents‡         | Tranexamic Acid                                                              | Tranexamic Acid                                                              | Tranexamic Acid, PCC, rVIIa                                                   |
| Haemostaseology Team§           | May/May not                                                                 | May/May not                                                                 | Yes                                                                          |
| Lab based screening tests¶      | Hemoglobin/Platelet count                                                   | Fibrinogen/PT/APTT/D Dimer                                                 | Factor assays/Aggregometer/Verify now                                         |
| POC investigations¶             | 4 red cells on top of blood order schedule                                   | 8 red cells on top of blood order schedule                                   | Hb/VET/Verify Now/Multiplete/ROTEM platelet                                 |

HCF: Health care facility; VET: Viscoelastic Testing; Hb: Hemoglobin. * - Depicts Standard Operating Procedure or commonly accepted and validated protocol or algorithm. †Blood bank that makes blood components like packed red cells, fresh frozen plasma, platelet concentrate (PC) and cryoprecipitate available for patient use. ‡Pharmacological agents include tranexamic acid (TxA), epsilon aminocaproic acid (EACA), prothrombin complex concentrate (PCC), fibrinogen concentrate, single factor concentrates (e.g., factor VIII, IX, XII, rFVIIa - recombinant factor VIIa) and antidotes for certain drugs that may cause bleeding (e.g., protamine, PCC - prothrombin complex concentrate). §Haemostaseology team including anesthetists, intensivists, transfusion medicine and surgeons as mandatory and preferred presence of a lab hematologists and/or a clinical hematologist. ¶Lab based screening test include blood cell count (Hb & PLC), PT, APTT, Fibrinogen, D-Dimer, single factor analysis and platelet function testing. †POC investigations include ACT, viscoelastic testing (global coagulation tests) and platelet function testing. Timely and appropriate transfer of patient to health care centers which are capable of and experienced in dealing with patients suffering from abnormal bleeding

underlying clinical setting. With the better understanding of the pathophysiology of hemorrhagic shock, resuscitation of patients with massive hemorrhage has advanced from reactive, supportive treatment (crystalloid, packed red cells, laboratory tests-based use of coagulation factors) to use of proactive standardized protocols called massive transfusion protocols (MTP). MTPs aim at curbing or eliminating the potential threat of acidosis, hypothermia and coagulopathy that eventually appears in these settings.

Shock packs have a predefined ratio (1:1:1 or 2:1:1) of RBCs, FFP/cryoprecipitate and platelet units (random donor) for transfusion. Currently, 1:1:1 ratio (1 unit each of packed red cells, Fresh Frozen Plasma and Platelet (Single donor)) is the most commonly adopted MTP concept in India. However, it must be considered that, fixed-ratio MTPs have certain limitations. First, they are not standardized, i.e., the trigger for initiating or stopping the protocol as well as the optimum ratio of blood components is non-uniform. Second, if an MTP is triggered for a non-massive blood loss situation, it may lead to wastage of blood products and over-transfusion resulting in transfusion-associated circulatory overload (TACO), which is a major reason for transfusion-associated morbidity and mortality. The expert group agrees that the trigger for initiating an MTP should be defined and standardized. The obligation of developing such triggers of transfusion is on respective medical associations dealing with different clinical fraternities.

One significant limitation of standard coagulation tests in the management of massive hemorrhage is the long turn-around-time of 45-90 minutes; also, efficacy of MTPs is assessed by means that are not standardized or validated. Shock packs gain importance in the early phase of massive hemorrhage when point-of-care viscoelastic testing results are not available. The expert group agrees that waiting for POCT results until the blood loss is 1-1.5 liters (like in case of PPH) could avoid unnecessary and irrational administration of shock packs early and wouldn’t further complicate the coagulopathy. However, since there is no POCT available for goal-directed bleeding management in most Indian hospitals to replace empirical transfusion, the expert group recommends defining the composition and triggers of shock packs for centers with no availability of or
access to viscoelastic testing. The stop criteria for an MTP should also be predefined in case of bleeding control based on physiological criteria (hemodynamic status and/or laboratory values) or a decision that further resuscitation is likely to be futile.

**Recommendations for specific clinical settings**

**Obstetric hemorrhage**

Obstetric hemorrhage is one of the most common causes of maternal mortality in developing countries, including India. Obstetric hemorrhage most often occurs in the peripartum, particularly in the postpartum period. In most institutions, severe postpartum hemorrhage (PPH) is defined as blood loss of more than 1500 ml, or a fall in hemoglobin more than 4 g/dl after acute blood loss in a parturient. Current concepts of bleeding management in military hemorrhage have been transferred to PPH, where the tendency is to use PRBCs and FFP in the ratio of 1:1 with early use of platelets. It is arguable whether FFP transfusion is reasonable at all in PPH due to a higher fibrinogen plasma concentration in pregnant women compared to the blood donors. The 2016 ISTH guideline on the management of coagulopathy associated with PPH recommends not to transfuse FFP if POC or laboratory tests of hemostasis are normal. A massive bleeding protocol should be present and implemented in all obstetric departments and delivery rooms. This protocol/algorith should be adapted to local expertise and the availability of diagnostic tools and therapeutic interventions. The massive transfusion ‘pack’ consisting of four units of O-negative PRBCs, four units of AB FFP, and one apheresis platelets should ideally be available. Here, fibrinogen concentrate, and prothrombin complex concentrate could replace FFP in these transfusion packs and may improve bleeding management in PPH, significantly. The expert group agrees that the two most important reasons for obstetrics hemorrhage-related morbidity and mortality are, first, the absence of blood banks in rural areas or the delay in/inability to transfer bleeding parturient to centers with a blood bank and second, the unavailability of coagulation testing facilities around the clock for guiding bleeding management with appropriate blood components. The expert group recommends that bleeding management protocols or guidelines need to be developed in a manner to address all issues of suboptimal treatment and outcome of bleeding parturient. A PPH management flowchart is presented in Figure 1.

**Liver surgery and transplantation**

Liver surgery and transplantation has been associated with large amounts of blood loss in the past. However, with increased expertise, refined surgical skills and improved hemostatic management, the blood loss and subsequent transfusion requirements are decreasing worldwide. In India, liver transplant programs are evolving at most centers. There are high transfusion requirements and transfusion-associated complications based on in-house blood bank and appropriate facilities for coagulation testing. There is a general awareness regarding the usefulness of POC viscoelastic testing devices to monitor and guide hemostasis and bleeding management in these patients. The expert group recommends that it should be mandatory to have POC viscoelastic testing devices in or near the operating room and ICU for such patients. Furthermore, validated bleeding management algorithms should be followed during surgery and post-operatively.
Trauma and ICU
The expert group agrees that management of bleeding trauma patients needs to be improved in India. Both central and state governments in India are developing dedicated trauma centers in various states. Accordingly, it would be easy and worthwhile at the time of formation of these centers to implement protocolled, guideline-concordant management of trauma-induced coagulopathy and bleeding management in these centers. This could include the blood banks/blood storage facilities, coagulation testing facilities and availability of point-of-care viscoelastic testing devices.

Cardiothoracic and vascular surgery/Cardiovascular ICU
Postoperative bleeding is a common and severe complication in cardiac surgery, resulting in emergency re-exploration in about 5% of cases. The risk factors for abnormal bleeding in cardiovascular procedures include age, anemia, thrombocytopenia, complex procedures (redo-coronary artery bypass graft surgery, redo-valve replacement thoracic aortic procedures), medications (antiplatelet/anticoagulant), and comorbidities. Pre-operative interventions aimed to reduce the bleeding risk include treating anemia, opting off-pump or less invasive surgical techniques, discontinuation of antiplatelet drugs and treatment of co-morbidities. The expert group suggests that Aspirin should be continued throughout CABG. Stopping aspirin should be considered in patients at high risk of bleeding or those refusing blood transfusion. For patients taking P2Y12 receptor antagonists, postponing non-emergent surgery for 3 days after discontinuation of ticagrelor, 5 days after clopidogrel, and 7 days after prasugrel should be considered. Modifications in CPB, like the use of minimally invasive extracorporeal circuit (MiECC), cell salvage, heparin level-guided anticoagulation, modified ultrafiltration, autologous priming and normothermia reduce the risk of bleeding. In bleeding patients with coagulation factor deficiency, FFP, PCC, cryoprecipitate or fibrinogen concentrate administration may be considered. Viscoelastic testing, particularly TEG and ROTEM, provide real time quantitative global assessment of clotting function, and have led to the development of algorithms to diagnose and treat coagulopathy during and after cardiac surgery.

Conclusions
The multidisciplinary expert group evaluated the current practices and protocols of management of abnormal bleeding, in various clinical settings, across India. Owing to the diverse healthcare facilities, it is difficult to implement the international guidelines for the management of massive blood loss in India. In this first phase of the exercise, all experts developed a skeleton framework of guidelines for different levels of health care. Some of the key consensus statements could be summarized as follows:

A. The health education curriculum needs to incorporate holistic, multidisciplinary approach for management of abnormal bleeding.
B. A quick, representative clinical history is a very effective tool for predicting risk of abnormal bleeding before a surgical intervention.
C. Bleeding Time (BT) is an ineffective screening tool for pre-operative risk assessment.
D. Platelet function alterations are common and need to be picked up adequately and appropriately.
E. The role of coagulation laboratories and the timely use of POC Viscoelastic testing is vital.
F. The availability of resources to deal with a case of perioperative abnormal bleeding should be based on the level of health care facility.
G. The triggers for transfer from rural hospitals to appropriate centers must be predefined and standardized.
H. Shock packs and MTPs need a uniform, widely available and acceptable definition from the developing countries’ perspective.
I. Specific clinical settings, like trauma, obstetric hemorrhage or cardiac and liver surgeries, must be dealt as per validated protocols. Such protocols need to be designed in a manner so as to have a wider incorporation of inputs and better acceptability thereby ensuring uniform, validated practices across all geographical domains and clinical settings.
J. Perioperative bleeding management should be implemented in a timely manner in order to increase patients’ safety.

Development, adoption, and implementation of Patient blood management guidelines in a standardized and uniform manner is the pressing priority for a developing country like India and all the stakeholders must work towards it collectively.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Hilditch WG, Asbury AJ, Crawford JM. Pre-operative screening: Criteria for referring to anaesthetists. Anesthesia 2003;58:117-24.
2. Mendes FF, Machado EL, Oliveira M, Brasil FR, Eizerik G, Telöken P. Pre-operative screening: Evaluation by questionnaire. Braz J Anesthesiol 2013;63:347-51.
3. Karim HM. Practice and reasons for routine pre-operative
investigations among anesthesiologists and surgeons: An online survey. Indian J Anaesth 2017;61:933-5.
4. Shen L, Tabaie S, Ivascu N. Viscoelastic testing inside and beyond the operating room. J Thorac Dis 2017;9:5299-308.
5. Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor hemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev 2016;8:CD007871.
6. Crochemore T, Savioli FA. Thromboelastometry-guided hemostatic therapy for hemorrhagic shock in the postoperative period of vascular surgery: A case report. J Med Case Rep 2018;12:153.
7. Whiting P, Maiwenn AI, Westwood M, Ramos JC, Ryder S, Armstrong N, et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: A systematic review and cost-effectiveness analysis. Health Technol Assess 2015;19:1-228.
8. Inaba K, Rizoli S, Veigas PV, Callum J, Davenport R, Hess J, et al. 2014 Consensus conference on viscoelastic test-based transfusion guidelines for early trauma resuscitation: Report of the panel. J Trauma Acute Care Surg 2015;78:1220-9.
9. Neute D, Roque J. Clinical evaluation of bleeding and bruising in primary care. Am Fam Physician 2016;93:279-86.
10. Koscielny J, Ziemer S, Radtke H, Schmutzler M, Pruss A, Sinha P, et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004;10:195-204.
11. Koscielny J, von Tempelhoff GF, Ziemer S, Radtke H, Schmutzler M, Sinha P, et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004;10:155-66.
12. Bonhomme F, Boehlen F, Clergue F, de Moerloose P, et al. Preoperative hemostatic assessment: A new and simple bleeding questionnaire. Can J Anaesth 2016;63:1007-15.
13. Woll C, Smith PB, Fox JW. Epidemiology of preoperative hematologic assessment of children cared for in a pediatric emergency department. Am J Emerg Med 2018;36:33-7.
14. Adams AJ, Baldwin KD, Arkader A, Sankar WN. Assessing the need for common perioperative laboratory tests in pediatric patients with femoral shaft fractures. J Pediatr Orthop 2019;39:e456-61.
15. Vries MJ, van der Meijsen PE, Kuiper GJ, Nelemans PJ, Wetzels RJF, van Oerle RG, et al. Preoperative screening for bleeding disorders: A comprehensive laboratory assessment of clinical practice. Res Pract Thromb Haemos 2018;2:767-77.
16. Elbatarny M, Mollah S, Grabel J, Bae S, Deforest M, Tuttle A, et al. Normal range of bleeding scores for the ISTH-BAT: Adult and pediatric data from the merging project. Hemophilia 2014;20:831-5.
17. Palmer RL. Laboratory diagnosis of bleeding disorders. Basic screening tests. Postgrad Med 1984;76:137-42, 147-8.
18. Dötsch TM, Dirkmann D, Bezinoover D, Hartmann M, Treckmann JW, Paul A, et al. Assessment of standard laboratory tests and rotational thromboelastometry for the prediction of postoperative bleeding in liver transplantation. Br J Anaesth 2017;119:402-10.
19. Haas T, Fries D, Tanaka KA, Asmis L, Curry NS, Schöchl H. Usefulness of standard plasma coagulation tests in the management of perioperative coagulopathic bleeding: Is there any evidence? Br J Anaesth 2015;114:217-24.
20. Kinra P, Tewari V, Ramam RTS. Role of bleeding time and clotting time in preoperative hemostasis evaluation. IAISM 2009;53:56-61.
21. Keshavan VH, Swamy CM. Pre-operative laboratory testing. A prospective study on comparison and cost analysis. Indian J Anaesth 2016;60:838-42.
22. Kitchens CS. To bleed or not to bleed? Is that the question for the PTT? J Thromb Haemos 2005;3:2607-11.
23. Malbora B, Bilalolaghi E. Lupus anticoagulant positivity in pediatric patients with prolonged activated partial thromboplastin time: A single-center experience and review of literature. Pediatr Hematol Oncol 2015;32:495-504.
24. Hayward CPM, Moffat KA. Laboratory testing for bleeding disorders: Strategic uses of high and low-yield tests. Int J Lab Hem 2013;35:322-33.
25. Leahy MF, Hofmann A, Towler S, Trentino KM, Burrows SA, Swain SG, et al. Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: A retrospective observational study in four major adult tertiary-care hospitals. Transfusion 2017;57:1347-58.
26. Leahy MF, Roberts H, Mukhtar SA, Farmer S, Tovey J, Jewlachow V, et al. A pragmatic approach to embedding patient blood management in a tertiary hospital. Transfusion 2014;54:1133-45.
27. Althoff FC, Neb H, Herrmann E, Trentino KM, Vernich L, Füllenaub C, et al. Multimodal patient blood management program based on a three-pillar strategy: A systematic review and meta-analysis. Ann Surg 2019;269:794-804.
28. National Blood Authority Australia. National Blood Management Implementation Strategy 2017-2021. Better Management of patients’ blood … Better patient outcomes. 2017. Available from: https://www.blood.gov.au/implementing-pbm.
29. European Commission, Directorate-General for Health and Food Safety. Building National Programmes of Patient Blood Management (PBM). A Guide for Health Authorities. Publications Office of the European Union, Luxembourg, March 2017. Available from: https://ec.europa.eu/health/sites/health/files/blood_tissues_ organs/docs/2017_eupbm_authorities_en.pdf.
30. European Commission, Directorate-General for Health and Food Safety. Supporting Patient Blood Management (PBM) in the EU. A Practical Implementation Guide for Hospitals. Publications Office of the European Union, Luxembourg, March 2017. Available from: https://ec.europa.eu/health/sites/health/files/blood_tissues_ organs/docs/2017_eupbm_authorities_en.pdf.
31. Raymer JM, Flynn LM, Martin RF. Massive transfusion of blood in the surgical patient. Surg Clin North Am 2012;92:221-34.
32. Chidester SJ, Williams N, Wang W, Groner JI. A pediatric massive transfusion protocol. J Trauma Acute Care Surg 2012;73:1273-7.
33. Massive transfusion protocol (MTP) for hemorrhagic shock. ASA committee on blood management. Available from: https://www.ashq.org/For-Members/About-ASA/ASA-Committees/Committee-on-Blood-Management.aspx. [Last accessed on 2014 Sep 27].
34. Mitra B, Cameron PA, Gruen RL, Mori A, Fitzgerald M, Street A, et al. The definition of massive transfusion in trauma: A critical variable in examining evidence for resuscitation. Eur J Emerg Med 2011;18:137-42.
35. Sharpe JP, Weinberg J, Magnotti LJ, Croce MA, Fabian TC. Toward a better definition of massive transfusion: Focus on the interval of hemorrhage control. J Trauma Acute Care Surg 2012;73:1553-7.
36. Neff LP, Cannon JW, Morrison JJ, Edwards MJ, Spinella PC, Borgman MA, et al. Clearly defining pediatric massive transfusion: Cutting through the fog and friction with combat data. J Trauma Acute Care Surg 2015;78:22-8; discussion 28-29.
37. Moreno AM, Hampton D, Diggis B, Kiraly L, Fox EE, Holcomb JB, et al. Recursive partitioning identifies greater than 4 U of packed red blood cells per hour as an improved massive transfusion definition. J Trauma Acute Care Surg 2015;79:920-4.
38. Rosenfeld E, Lau J, Zhang W, Russell RT, Shah SR, Naik-Mathuria B, et al. Defining massive transfusion in civilian pediatric trauma. J Pediatr Surg 2019;54:975-9.
39. Patil V, Shethmahajan M. Massive transfusion and massive
transfusion protocol. Indian J Anaesth 2014;58:590-95.
40. Nunez TC, Young PB, Holcomb JB, Cotton BA. Creation, implementation, and maturation of a massive transfusion protocol for the exsanguinating trauma patient. J Trauma 2010;68:4498-505.
41. O’Keeffe T, Refai M, Tchorz K, Forester JE, Sarode R, et al. A massive transfusion protocol to decrease blood component use and costs. Arch Surg 2008;143:686-90.
42. Nascimento B, Callum J, Tien H, Rubenfeld G, Pinto R, Lin Y, et al. Effect of a fixed-ratio (1:1:1) transfusion protocol versus laboratory-results-guided transfusion in patients with severe trauma: A randomized feasibility trial. CMAJ 2013;185:E583-9.
43. Inaba K, Branco BC, Rhee P, Blakbourne LH, Holcomb JB, Teixeira PG, et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg 2010;210:957-65.
44. Wiersum-Osselton JC, Whitaker B, Grey S, Land K, Perez G, Rajbhandary S, et al. Revised international surveillance case definition of transfusion-associated circulatory overload: A classification agreement validation study. Lancet Haematol 2019;6:e350-8.
45. Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) hemovigilance and progress is improving transfusion safety. Br J Haematol 2013;163:303-14.
46. Clifford L, Jia Q, Subramanian A. Risk factors and clinical outcomes associated with perioperative transfusion-associated circulatory overload. Anesthesiology 2017;126:409-18.
47. Davenport R, Manson J, De’ath H, Platton S, Coates A, Allard S, et al. Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med 2011;39:2652-8.
48. Haas T, Spielmann N, Mauch J, Madjdpour C, Speer O, Schmugge M, et al. Comparison of thromboelastometry (ROTEM®) with standard plasmas coagulation testing in pediatric surgery. Br J Anaesth 2012;108:36-41.
49. Gratz J, Güting H, Thröst S, Brazinova A, Görlinger K, Schäfer N, et al. Protocolized thromboelastometric-guided hemostatic management in patients with traumatic brain injury: A pilot study. Anaesthesia 2019;74:883-90.
50. Johansson PI, Stensballe J, Oliveri R, Wade CE, Ostrowski SR, Holcomb JB, et al. How I treat patients with massive hemorrhage. Blood 2014;124:3052-8.
51. McNamara H, Kenyon C, Smith R, Mallaiah S, Barclay P. Obstetric hemorrhage. In: Johnston I, Harrop-Griffiths W, Gemmell L, editors. AAGBI Core Topics in Anaesthesia. Chichester: Wiley-Blackwell Ltd.; 2012. p. 105-23.
52. Huissoud C, Carrabin N, Benchail M, Fontaine O, Levrat A, Massignon D, et al. Coagulation assessment by rotation thromboelastometry in normal pregnancy. Thromb Haemost 2009;101:755-761.
53. Collis R. Coagulation point-of-care testing on the labor ward should be mandatory. Int J Obstet Anesth 2016;27:66-9.
54. Chidananda Swamy NM. Blood transfusion practices in liver transplantation. Indian J Anaesth 2014;58:647-51.
55. Bell SE, Kitchen T, John M, Scarr C, Kelly K, Bailey C, et al. Designing and implementing an all Wales postpartum hemorrhage quality improvement project: OBS Cymru (the Obstetric Bleeding Strategy for Wales). BMJ Open Qual 2020;9:e000854.
56. GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1775-812.
57. Levy D. Obstetric hemorrhage. In: Johnston I, Harrop-Griffiths W, Gemmell L, editors. AAGBI Core Topics in Anaesthesia. Chichester: Wiley-Blackwell Ltd.; 2012. p. 105-23.
58. Barnett-Magnus PH, Cohen H. Serious Hazards of Transfusion (SHOT) hemovigilance and progress is improving transfusion safety. Br J Anaesth 2018;120:50-56.
59. Bolton-Maggs PH, Cohen H, Davenport R, Manson J, De’ath H, Platton S, Coates A, Allard S, et al. Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med 2011;39:2652-8.
60. Clift R, Giannopoulos A, Moxham J, Million M, Lu M, et al. Effect of a fixed-ratio (1:1:1) transfusion protocol versus laboratory-results-guided transfusion in patients with severe trauma: A randomized feasibility trial. CMAJ 2013;185:E583-9.
61. Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Teixeira PG, et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg 2010;210:957-65.
62. Wiersum-Osselton JC, Whitaker B, Grey S, Land K, Perez G, Rajbhandary S, et al. Revised international surveillance case definition of transfusion-associated circulatory overload: A classification agreement validation study. Lancet Haematol 2019;6:e350-8.
63. Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) hemovigilance and progress is improving transfusion safety. Br J Anaesth 2018;120:50-56.
64. Clift R, Giannopoulos A, Moxham J, Million M, Lu M, et al. Effect of a fixed-ratio (1:1:1) transfusion protocol versus laboratory-results-guided transfusion in patients with severe trauma: A randomized feasibility trial. CMAJ 2013;185:E583-9.
65. Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Teixeira PG, et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg 2010;210:957-65.
66. Buxton R, Kitchen T, John M, Scarr C, Kelly K, Bailey C, et al. Designing and implementing an all Wales postpartum hemorrhage quality improvement project: OBS Cymru (the Obstetric Bleeding Strategy for Wales). BMJ Open Qual 2020;9:e000854.
67. GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1775-812.
68. Levy D. Obstetric hemorrhage. In: Johnston I, Harrop-Griffiths W, Gemmell L, editors. AAGBI Core Topics in Anaesthesia. Chichester: Wiley-Blackwell Ltd.; 2012. p. 105-23.
69. Huissoud C, Carrabin N, Benchail M, Fontaine O, Levrat A, Massignon D, et al. Coagulation assessment by rotation thromboelastometry in normal pregnancy. Thromb Haemost 2009;101:755-761.
70. Collis R. Coagulation point-of-care testing on the labor ward should be mandatory. Int J Obstet Anesth 2016;27:66-9.
71. Chidananda Swamy NM. Blood transfusion practices in liver transplantation. Indian J Anaesth 2014;58:647-51.
72. Bell SE, Kitchen T, John M, Scarr C, Kelly K, Bailey C, et al. Designing and implementing an all Wales postpartum hemorrhage quality improvement project: OBS Cymru (the Obstetric Bleeding Strategy for Wales). BMJ Open Qual 2020;9:e000854.
75. Avkan-Oguz V, Ozkardesler S, Unek T, Ozbilgin M, Akan M, Firuzan E, et al. Risk factors for early bacterial infections in liver transplantation. Transplant Proc 2013;45:993-7.
76. Van Hoek B, de Rooij BJ, Verspaget HW. Risk factors for infection after liver transplantation. Best Pract Res Clin Gastroenterol 2012;26:61-72.
77. Davis JPE, Northup PG, Caldwell SH, Intagliata NM. Viscoelastic testing in liver disease. Ann Hepatol 2018;17:205-13.
78. Walsh M, Thomas SG, Howard JC, Evans E, Guyer K, Medvecz A, et al. Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastography. J Extra-Corp Technol 2011;43:162-7.
79. Stein P, Kaserer A, Sprengel K, Wanner GA, Seifert B, Theusinger OM, et al. Change of transfusion and treatment paradigm in major trauma patients. Anaesthesia 2017;72:1317-26.
80. Innerhofer P, Fries D, Mittermayr M, Innerhofer N, von Langen D, Hell T, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): A single-center, parallel-group, open-label, randomized trial. Lancet Haematol 2017;4:e258-71.
81. Colson PH, Gaudard P, Fellahi JL, Bertet H, Fauconie M, Amour J, et al. Active bleeding after cardiac surgery: A prospective observational multicenter study. PLoS One 2016;11:e0162396
82. Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer C, Meesters MI, Milojevic M, Benedetto U, Bolliger D, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth 2018;32:88-120.
83. Desborough M, Sandu R, Brunskill SJ, Doree C, Trivella M, Montedori A, et al. Fresh frozen plasma for cardiovascular surgery. Cochrane Database Syst Rev 2015;7:CD007614.